-

01:21:12 PM

COEP Stock News

COEP - Coeptis Therapeutics Holdings Inc

09/27/23 7:30 AM

Nasdaq : COEP

conferenceslow float

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Colleen Delaney, MD, MSc, Chief Scientific and Medical Officer, will present at the 2023 Cell& Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt...

RHEA-AI

neutral

09/14/23 7:30 AM

Nasdaq : COEP

clinical trialcovid-19low float

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative...

RHEA-AI

neutral

09/11/23 7:30 AM

Nasdaq : COEP

low float

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Deverra...

RHEA-AI

neutral

08/30/23 1:00 PM

Nasdaq : COEP

managementlow float

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for...

RHEA-AI

neutral

08/17/23 7:30 AM

Nasdaq : COEP

low float

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Holdings, Inc., a...

RHEA-AI

neutral

08/01/23 8:00 AM

Nasdaq : COEP

low float

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has submitted a 513 request to the U.S. Food and Drug Administration for an in vitro companion...

RHEA-AI

neutral

06/16/23 4:00 PM

Nasdaq : COEP

low float

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and...

RHEA-AI

neutral

06/14/23 9:28 AM

Nasdaq : COEP

low float

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and...

RHEA-AI

neutral

06/09/23 7:00 AM

Nasdaq : COEP

low float

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today that it received approval from the Nasdaq Stock Market of the Company's request to transfer its listing to the...

RHEA-AI

neutral

05/17/23 8:30 AM

Nasdaq : COEP

managementlow float

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the...

RHEA-AI

neutral